Short Paper: ChemopreventionCancer chemopreventive activity of the prenylated coumarin, umbelliprenin, in vivoIranshahi, Mehrdada; Sahebkar, Amirhosseina; Takasaki, Midorib c; Konoshima, Takaob c; Tokuda, Harukunib cAuthor Information aDepartment of Pharmacognosy, Biotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran bDepartment of Pharmacology, Chiba Institute of Science, Chiba cDepartment of Molecular Biochemistry, Kyoto Prefectural University of Medicine, Kamigyo-ku, Kyoto, Japan Correspondence to Dr Mehrdad Iranshahi, Vakilabad Boulevard, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, PO Box 91775-1365, Iran Tel: +98 511 8823255 66; fax: +98 511 8823251; e-mail: [email protected] Received 12 March 2009 Accepted 29 March 2009 European Journal of Cancer Prevention: September 2009 - Volume 18 - Issue 5 - p 412-415 doi: 10.1097/CEJ.0b013e32832c389e Buy Metrics Abstract Umbelliprenin is a prenylated compound, which belongs to the class of sesquiterpene coumarins. In continuation of our earlier in-vitro finding, we determined to assess the cancer chemopreventive activity of umbelliprenin in vivo by using a two-stage carcinogenesis assay of mouse skin tumors induced by peroxynitrite as an initiator and TPA (12-O-tetradecanoylphorbol-13-acetate) as a promoter. In this assay, treatment with umbelliprenin along with peroxynitrite/TPA delayed the formation of papillomas up to week 9, and approximately 33.3 and 86.6% of the mice bore papillomas after 11 and 20 weeks of promotion, respectively. Umbelliprenin reduced the number of tumors per mouse by 45% after 20 weeks of promotion compared with the control group. Interestingly, this is equal to the corresponding value (45%) for curcumin, used as a reference standard compound in our study. In addition, the pattern of tumor promotion was slower in mice treated with umbelliprenin compared with the curcumin. Therefore, umbelliprenin might be valuable as a cancer chemopreventive agent. © 2009 Lippincott Williams & Wilkins, Inc.